Open AccessViibryd (Vilazodone): Viable option or for the byrds?
Author(s) -
Misty L. Gonzalez
Publication year - 2011
Publication title -
mental health clinician
Language(s) - English
Resource type - Journals
ISSN - 2168-9709
DOI - 10.9740/mhc.n89810
Subject(s) - food and drug administration , medicine , drug , adverse effect , clinical trial , pharmacology , intensive care medicine
Vilazodone was approved by the Food and Drug Administration (FDA) in January of 2011. This article reviews clinically significant aspects of this new drug including: the FDA-approved indications, mechanism of action, administration, drug interactions, adverse effects, clinical trial evidence, innovative properties and place in therapy.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom